All In Biotech

Drug Trial Radar · NCT06217562

Vasopressin for Septic Shock Pragmatic Trial

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,959 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,959

Actual

Start

Feb 1, 2024

Primary completion

Feb 17, 2026

Study completion Jun 6, 2026

Sponsor

Lead sponsor
Intermountain Health Care, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Utah
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.

Conditions

  • Septic Shock

Interventions

  • VasopressinDrug

    Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.

  • Recommendation to use a lower initiation threshold for vasopressinOther

    Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)

  • Recommendation to use a higher initiation threshold for vasopressinOther

    Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day all-cause mortalityTime frame: 28 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Cassia Regional Hospital

    Burley, Idaho

  • American Fork Hospital

    American Fork, Utah

  • Cedar City Hospital

    Cedar City, Utah

  • Layton Hospital

    Layton, Utah

  • Logan Regional Hospital

    Logan, Utah

  • Intermountain Medical Center

    Murray, Utah

  • McKay-Dee Hospital

    Ogden, Utah

  • Park City Hospital

    Park City, Utah

  • Utah Valley Hospital

    Provo, Utah

  • Riverton Hospital

    Riverton, Utah

  • LDS Hospital

    Salt Lake City, Utah

  • Alta View Hospital

    Sandy City, Utah

  • St. George Regional Hospital

    St. George, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.